Knight Therapeutics Inc T.GUD

Buzz on the Bullboards: TSX hits new high amid holiday optimism and sector disparities

[Jonathon Brown]

This past week, the TSX reached a new intraday high, reflecting a buoyant market sentiment as investors gear up for the holiday season. read article.

[GoldenInvestor]

Paladin labs   15 years in. -rev $31.8 M EBITDA -  $15.9 M     Knight Therapeutics  10 years in - $271 million rev EBITDA -over $42 million  

[Possibleidiot01]

Knight Therapeutics Inc. (TSE:GUD - Get Free Report) Director Samira Sakhia bought 20,000 shares of Knight Therapeutics stock in a transaction on Monday, November 11th. The shares were acquired at an

[gudisgood]

Thanks for pointing this out! It's been a long process.

[gudisgood]

I'm with you. Although an uneventful quarter in terms of business development, it was a solid quarter in terms of results, and aligns with the financial guidance given earlier. We knew there

[Stockoman1]

I hear you.  6 year and still awaiting the day. Maybe when the grandchildren gradute from college !  

[EbbFlow88]

I'm actually a bit surprised by the market's reaction. Book value increased to roughly $7.70/share. It's the 3rd straight quarter of operating profit which is the most important metric as

[longrun86]

Tales of glory will most certainly not be written about Knight's Q3 performance. I am still holding my shares. I am looking forward to the day when it finally signals that it will be a

[EbbFlow88]

Knight filed a notice of appeal to the Tax Court of Canada in December 2021. The appeal hearing is scheduled for April 2025.

[PressRelease]

MONTREAL, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its third quarter ended September 30, 2024. All currency amounts are in thousands...read article.

[PressRelease]

MONTREAL, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its third quarter 2024 financial results on Thursday, November 7, 2024, prior to market opening. Following the release, Knight...read article.

[Chianchin]

...and what ebb and no flows did not comment on is that GUD has not made a dime in profits and the ammount of cash keeps declining every year. Ten years ago GUD had close to one billion dolalrs in

[EbbFlow88]

It's amazing that GUD is still trading in the 5's. Since GBT purchase in 2020.... Sales have gone from 200M to 350M Shares outstanding have gone from 140M to 100M Gross Margin from 41% to

[PressRelease]

MONTREAL, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Mexican affiliate, Grupo Biotoscana de Especialidad S.A. de C.V. has obtained regulatory approval by COFEPRIS, the Mexican...read article.

[wofats]

Just poking the bear. How do you explain something like this ? There is some monies to be made isn't there? Filed 2024-09-21 18:37   Tx date 2024

[EbbFlow88]

Looks like they've slowed down the buybacks recently. I noticed at the beginning of October that they were buying back shares again in the first couple of days in a big way and then nothing since.